TCTAP 2026 Sponsors

Within two decades, MicroPort has transformed itself from a market follower, into a global leader in the field of Percutaneous Coronary Intervention PCI. Its proprietary Firehawk targeted eluting stent system, with proven clinical evidence in terms of safety and efficacy, has become a leading stent, setting industry standards for a new generation of global cardiac stents.

MicroPort CardioFlow established in 2015, is dedicated to providing advanced minimally invasive therapies for structural heart diseases. Our vision, is to bring cutting edge technologies into treatment development, in order to optimize clinical outcomes, and improve patients quality of life, with reliable, superior and accessible solutions.